BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bhattacharyya A, Ear US, Koller BH, Weichselbaum RR, Bishop DK. The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem 2000;275:23899-903. [PMID: 10843985 DOI: 10.1074/jbc.C000276200] [Cited by in Crossref: 406] [Cited by in F6Publishing: 196] [Article Influence: 19.3] [Reference Citation Analysis]
Number Citing Articles
1 Spiro C, McMurray CT. Nuclease-deficient FEN-1 blocks Rad51/BRCA1-mediated repair and causes trinucleotide repeat instability. Mol Cell Biol 2003;23:6063-74. [PMID: 12917330 DOI: 10.1128/MCB.23.17.6063-6074.2003] [Cited by in Crossref: 60] [Cited by in F6Publishing: 32] [Article Influence: 3.3] [Reference Citation Analysis]
2 Hawsawi YM, Al-Numair NS, Sobahy TM, Al-Ajmi AM, Al-Harbi RM, Baghdadi MA, Oyouni AA, Alamer OM. The role of BRCA1/2 in hereditary and familial breast and ovarian cancers. Mol Genet Genomic Med 2019;7:e879. [PMID: 31317679 DOI: 10.1002/mgg3.879] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
3 Huntoon CJ, Flatten KS, Wahner Hendrickson AE, Huehls AM, Sutor SL, Kaufmann SH, Karnitz LM. ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status. Cancer Res 2013;73:3683-91. [PMID: 23548269 DOI: 10.1158/0008-5472.CAN-13-0110] [Cited by in Crossref: 122] [Cited by in F6Publishing: 75] [Article Influence: 15.3] [Reference Citation Analysis]
4 Maxwell KN, Wubbenhorst B, Wenz BM, De Sloover D, Pluta J, Emery L, Barrett A, Kraya AA, Anastopoulos IN, Yu S, Jiang Y, Chen H, Zhang NR, Hackman N, D'Andrea K, Daber R, Morrissette JJD, Mitra N, Feldman M, Domchek SM, Nathanson KL. BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers. Nat Commun. 2017;8:319. [PMID: 28831036 DOI: 10.1038/s41467-017-00388-9] [Cited by in Crossref: 116] [Cited by in F6Publishing: 92] [Article Influence: 29.0] [Reference Citation Analysis]
5 Cheng WH, Kusumoto R, Opresko PL, Sui X, Huang S, Nicolette ML, Paull TT, Campisi J, Seidman M, Bohr VA. Collaboration of Werner syndrome protein and BRCA1 in cellular responses to DNA interstrand cross-links. Nucleic Acids Res 2006;34:2751-60. [PMID: 16714450 DOI: 10.1093/nar/gkl362] [Cited by in Crossref: 54] [Cited by in F6Publishing: 59] [Article Influence: 3.6] [Reference Citation Analysis]
6 Lu F, Hou Y, Chen Z, Jiang J, He X, Xia Y, Cao K, Chang L, Li W. Efficacy and Safety of Platinum-Based Chemotherapy as First-Line Therapy for Metastatic Triple-Negative Breast Cancer: A Meta-Analysis of Randomized Controlled Trials. Technol Cancer Res Treat 2021;20:15330338211016369. [PMID: 33977814 DOI: 10.1177/15330338211016369] [Reference Citation Analysis]
7 Tian F, Sharma S, Zou J, Lin SY, Wang B, Rezvani K, Wang H, Parvin JD, Ludwig T, Canman CE, Zhang D. BRCA1 promotes the ubiquitination of PCNA and recruitment of translesion polymerases in response to replication blockade. Proc Natl Acad Sci U S A 2013;110:13558-63. [PMID: 23901102 DOI: 10.1073/pnas.1306534110] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 4.1] [Reference Citation Analysis]
8 George SH, Shaw P. BRCA and Early Events in the Development of Serous Ovarian Cancer. Front Oncol 2014;4:5. [PMID: 24478985 DOI: 10.3389/fonc.2014.00005] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 5.3] [Reference Citation Analysis]
9 Cao X, Li C, Xiao S, Tang Y, Huang J, Zhao S, Li X, Li J, Zhang R, Yu W. Acetylation promotes TyrRS nuclear translocation to prevent oxidative damage. Proc Natl Acad Sci U S A 2017;114:687-92. [PMID: 28069943 DOI: 10.1073/pnas.1608488114] [Cited by in Crossref: 35] [Cited by in F6Publishing: 20] [Article Influence: 8.8] [Reference Citation Analysis]
10 De Silva IU, McHugh PJ, Clingen PH, Hartley JA. Defects in interstrand cross-link uncoupling do not account for the extreme sensitivity of ERCC1 and XPF cells to cisplatin. Nucleic Acids Res 2002;30:3848-56. [PMID: 12202770 DOI: 10.1093/nar/gkf479] [Cited by in Crossref: 90] [Cited by in F6Publishing: 85] [Article Influence: 4.7] [Reference Citation Analysis]
11 Yadav BS, Chanana P, Jhamb S. Biomarkers in triple negative breast cancer: A review. World J Clin Oncol 2015;6:252-63. [PMID: 26677438 DOI: 10.5306/wjco.v6.i6.252] [Cited by in CrossRef: 58] [Cited by in F6Publishing: 57] [Article Influence: 9.7] [Reference Citation Analysis]
12 Orthwein A, Noordermeer SM, Wilson MD, Landry S, Enchev RI, Sherker A, Munro M, Pinder J, Salsman J, Dellaire G, Xia B, Peter M, Durocher D. A mechanism for the suppression of homologous recombination in G1 cells. Nature 2015;528:422-6. [PMID: 26649820 DOI: 10.1038/nature16142] [Cited by in Crossref: 302] [Cited by in F6Publishing: 248] [Article Influence: 50.3] [Reference Citation Analysis]
13 Haynes B, Gajan A, Nangia-Makker P, Shekhar MP. RAD6B is a major mediator of triple negative breast cancer cisplatin resistance: Regulation of translesion synthesis/Fanconi anemia crosstalk and BRCA1 independence. Biochim Biophys Acta Mol Basis Dis 2020;1866:165561. [PMID: 31639439 DOI: 10.1016/j.bbadis.2019.165561] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
14 Tian M, Zhong Y, Zhou F, Xie C, Zhou Y, Liao Z. Platinum-based therapy for triple-negative breast cancer treatment: A meta-analysis. Mol Clin Oncol 2015;3:720-4. [PMID: 26137293 DOI: 10.3892/mco.2015.518] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
15 Chacón RD, Costanzo MV. Triple-negative breast cancer. Breast Cancer Res 2010;12 Suppl 2:S3. [PMID: 21050424 DOI: 10.1186/bcr2574] [Cited by in Crossref: 136] [Cited by in F6Publishing: 131] [Article Influence: 12.4] [Reference Citation Analysis]
16 Li Q, Saito TT, Martinez-Garcia M, Deshong AJ, Nadarajan S, Lawrence KS, Checchi PM, Colaiacovo MP, Engebrecht J. The tumor suppressor BRCA1-BARD1 complex localizes to the synaptonemal complex and regulates recombination under meiotic dysfunction in Caenorhabditis elegans. PLoS Genet 2018;14:e1007701. [PMID: 30383767 DOI: 10.1371/journal.pgen.1007701] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
17 Nagaraju G, Scully R. Minding the gap: the underground functions of BRCA1 and BRCA2 at stalled replication forks. DNA Repair (Amst) 2007;6:1018-31. [PMID: 17379580 DOI: 10.1016/j.dnarep.2007.02.020] [Cited by in Crossref: 73] [Cited by in F6Publishing: 62] [Article Influence: 5.2] [Reference Citation Analysis]
18 Gong C, Ma G, Hu X, Zhang Y, Wang Z, Zhang J, Zhao Y, Li Y, Xie Y, Yang Z, Wang B. Pretreatment 18F-FDG Uptake Heterogeneity Predicts Treatment Outcome of First-Line Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer. Oncologist 2018;23:1144-52. [PMID: 30082489 DOI: 10.1634/theoncologist.2018-0001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
19 Sun CK, Zhang F, Xiang T, Chen Q, Pandita TK, Huang Y, Hu MC, Yang Q. Phosphorylation of ribosomal protein S6 confers PARP inhibitor resistance in BRCA1-deficient cancers. Oncotarget 2014;5:3375-85. [PMID: 24831086 DOI: 10.18632/oncotarget.1952] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 4.3] [Reference Citation Analysis]
20 Dong C, Zhang F, Luo Y, Wang H, Zhao X, Guo G, Powell SN, Feng Z. p53 suppresses hyper-recombination by modulating BRCA1 function. DNA Repair (Amst) 2015;33:60-9. [PMID: 26162908 DOI: 10.1016/j.dnarep.2015.06.005] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
21 Evers B, Schut E, van der Burg E, Braumuller TM, Egan DA, Holstege H, Edser P, Adams DJ, Wade-Martins R, Bouwman P, Jonkers J. A high-throughput pharmaceutical screen identifies compounds with specific toxicity against BRCA2-deficient tumors. Clin Cancer Res 2010;16:99-108. [PMID: 20008842 DOI: 10.1158/1078-0432.CCR-09-2434] [Cited by in Crossref: 54] [Cited by in F6Publishing: 29] [Article Influence: 4.5] [Reference Citation Analysis]
22 Peluso S, Chiappetta G. High-Mobility Group A (HMGA) Proteins and Breast Cancer. Breast Care (Basel) 2010;5:81-5. [PMID: 20847819 DOI: 10.1159/000297717] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
23 Drost R, Dhillon KK, van der Gulden H, van der Heijden I, Brandsma I, Cruz C, Chondronasiou D, Castroviejo-Bermejo M, Boon U, Schut E, van der Burg E, Wientjens E, Pieterse M, Klijn C, Klarenbeek S, Loayza-Puch F, Elkon R, van Deemter L, Rottenberg S, van de Ven M, Dekkers DH, Demmers JA, van Gent DC, Agami R, Balmaña J, Serra V, Taniguchi T, Bouwman P, Jonkers J. BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1. J Clin Invest 2016;126:2903-18. [PMID: 27454287 DOI: 10.1172/JCI70196] [Cited by in Crossref: 66] [Cited by in F6Publishing: 39] [Article Influence: 13.2] [Reference Citation Analysis]
24 Ratanaphan A. A DNA repair BRCA1 estrogen receptor and targeted therapy in breast cancer. Int J Mol Sci 2012;13:14898-916. [PMID: 23203101 DOI: 10.3390/ijms131114898] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
25 Dhar S, Brosh RM. BLM's balancing act and the involvement of FANCJ in DNA repair. Cell Cycle 2018;17:2207-20. [PMID: 30209988 DOI: 10.1080/15384101.2018.1520567] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
26 Swanton C, Nicke B, Schuett M, Eklund AC, Ng C, Li Q, Hardcastle T, Lee A, Roy R, East P, Kschischo M, Endesfelder D, Wylie P, Kim SN, Chen JG, Howell M, Ried T, Habermann JK, Auer G, Brenton JD, Szallasi Z, Downward J. Chromosomal instability determines taxane response. Proc Natl Acad Sci U S A 2009;106:8671-6. [PMID: 19458043 DOI: 10.1073/pnas.0811835106] [Cited by in Crossref: 182] [Cited by in F6Publishing: 162] [Article Influence: 15.2] [Reference Citation Analysis]
27 Sirbu BM, Lachmayer SJ, Wülfing V, Marten LM, Clarkson KE, Lee LW, Gheorghiu L, Zou L, Powell SN, Dahm-Daphi J, Willers H. ATR-p53 restricts homologous recombination in response to replicative stress but does not limit DNA interstrand crosslink repair in lung cancer cells. PLoS One 2011;6:e23053. [PMID: 21857991 DOI: 10.1371/journal.pone.0023053] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
28 Domagala P, Hybiak J, Rys J, Byrski T, Cybulski C, Lubinski J. Pathological complete response after cisplatin neoadjuvant therapy is associated with the downregulation of DNA repair genes in BRCA1-associated triple-negative breast cancers. Oncotarget 2016;7:68662-73. [PMID: 27626685 DOI: 10.18632/oncotarget.11900] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
29 Wu Y, Brosh RM Jr. FANCJ helicase operates in the Fanconi Anemia DNA repair pathway and the response to replicational stress. Curr Mol Med 2009;9:470-82. [PMID: 19519404 DOI: 10.2174/156652409788167159] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 2.0] [Reference Citation Analysis]
30 Orelli BJ, Bishop DK. BRCA2 and homologous recombination. Breast Cancer Res 2001;3:294-8. [PMID: 11597317 DOI: 10.1186/bcr310] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis]
31 Reinhardt HC, Yaffe MB. Phospho-Ser/Thr-binding domains: navigating the cell cycle and DNA damage response. Nat Rev Mol Cell Biol 2013;14:563-80. [PMID: 23969844 DOI: 10.1038/nrm3640] [Cited by in Crossref: 188] [Cited by in F6Publishing: 148] [Article Influence: 23.5] [Reference Citation Analysis]
32 Romero I, Bast RC. Minireview: human ovarian cancer: biology, current management, and paths to personalizing therapy. Endocrinology. 2012;153:1593-1602. [PMID: 22416079 DOI: 10.1210/en.2011-2123] [Cited by in Crossref: 183] [Cited by in F6Publishing: 156] [Article Influence: 20.3] [Reference Citation Analysis]
33 Liu Y, Yasukawa M, Chen K, Hu L, Broaddus RR, Ding L, Mardis ER, Spellman P, Levine DA, Mills GB, Shmulevich I, Sood AK, Zhang W. Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma. JAMA Oncol 2015;1:486-94. [PMID: 26181259 DOI: 10.1001/jamaoncol.2015.1432] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
34 Rottenberg S, Nygren AO, Pajic M, van Leeuwen FW, van der Heijden I, van de Wetering K, Liu X, de Visser KE, Gilhuijs KG, van Tellingen O. Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. Proc Natl Acad Sci USA. 2007;104:12117-12122. [PMID: 17626183 DOI: 10.1073/pnas.0702955104] [Cited by in Crossref: 212] [Cited by in F6Publishing: 182] [Article Influence: 15.1] [Reference Citation Analysis]
35 Willers H, Taghian AG, Luo CM, Treszezamsky A, Sgroi DC, Powell SN. Utility of DNA repair protein foci for the detection of putative BRCA1 pathway defects in breast cancer biopsies. Mol Cancer Res 2009;7:1304-9. [PMID: 19671671 DOI: 10.1158/1541-7786.MCR-09-0149] [Cited by in Crossref: 96] [Cited by in F6Publishing: 47] [Article Influence: 8.0] [Reference Citation Analysis]
36 Wahba HA, El-Hadaad HA. Current approaches in treatment of triple-negative breast cancer. Cancer Biol Med. 2015;12:106-116. [PMID: 26175926 DOI: 10.7497/j.issn.2095-3941.2015.0030] [Cited by in F6Publishing: 146] [Reference Citation Analysis]
37 Cortesi L, Masini C, Cirilli C, Medici V, Marchi I, Cavazzini G, Pasini G, Turchetti D, Federico M. Favourable ten-year overall survival in a Caucasian population with high probability of hereditary breast cancer. BMC Cancer 2010;10:90. [PMID: 20219108 DOI: 10.1186/1471-2407-10-90] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 2.5] [Reference Citation Analysis]
38 Lee A, Moon BI, Kim TH. BRCA1/BRCA2 Pathogenic Variant Breast Cancer: Treatment and Prevention Strategies. Ann Lab Med 2020;40:114-21. [PMID: 31650727 DOI: 10.3343/alm.2020.40.2.114] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
39 Pal T, Vadaparampil ST. Genetic risk assessments in individuals at high risk for inherited breast cancer in the breast oncology care setting. Cancer Control 2012;19:255-66. [PMID: 23037493 DOI: 10.1177/107327481201900402] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
40 Hill SJ, Clark AP, Silver DP, Livingston DM. BRCA1 pathway function in basal-like breast cancer cells. Mol Cell Biol 2014;34:3828-42. [PMID: 25092866 DOI: 10.1128/MCB.01646-13] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 4.6] [Reference Citation Analysis]
41 Rosen MN, Goodwin RA, Vickers MM. BRCA mutated pancreatic cancer: A change is coming. World J Gastroenterol 2021;27:1943-58. [PMID: 34007132 DOI: 10.3748/wjg.v27.i17.1943] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Bertucci F, Finetti P, Birnbaum D. Basal breast cancer: a complex and deadly molecular subtype. Curr Mol Med. 2012;12:96-110. [PMID: 22082486 DOI: 10.2174/156652412798376134] [Cited by in Crossref: 120] [Cited by in F6Publishing: 97] [Article Influence: 13.3] [Reference Citation Analysis]
43 Robson ME, Chappuis PO, Satagopan J, Wong N, Boyd J, Goffin JR, Hudis C, Roberge D, Norton L, Bégin LR, Offit K, Foulkes WD. A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res 2004;6:R8-R17. [PMID: 14680495 DOI: 10.1186/bcr658] [Cited by in Crossref: 209] [Cited by in F6Publishing: 170] [Article Influence: 11.6] [Reference Citation Analysis]
44 Clark CC, Weitzel JN, O'Connor TR. Enhancement of synthetic lethality via combinations of ABT-888, a PARP inhibitor, and carboplatin in vitro and in vivo using BRCA1 and BRCA2 isogenic models. Mol Cancer Ther 2012;11:1948-58. [PMID: 22778154 DOI: 10.1158/1535-7163.MCT-11-0597] [Cited by in Crossref: 53] [Cited by in F6Publishing: 21] [Article Influence: 5.9] [Reference Citation Analysis]
45 Bonanno L. Predictive models for customizing chemotherapy in advanced non-small cell lung cancer (NSCLC). Transl Lung Cancer Res 2013;2:160-71. [PMID: 25806229 DOI: 10.3978/j.issn.2218-6751.2013.03.07] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
46 Kim D, Jung W, Koo JS. The expression of ERCC1, RRM1, and BRCA1 in breast cancer according to the immunohistochemical phenotypes. J Korean Med Sci 2011;26:352-9. [PMID: 21394302 DOI: 10.3346/jkms.2011.26.3.352] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
47 Juvekar A, Burga LN, Hu H, Lunsford EP, Ibrahim YH, Balmañà J, Rajendran A, Papa A, Spencer K, Lyssiotis CA, Nardella C, Pandolfi PP, Baselga J, Scully R, Asara JM, Cantley LC, Wulf GM. Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. Cancer Discov 2012;2:1048-63. [PMID: 22915751 DOI: 10.1158/2159-8290.CD-11-0336] [Cited by in Crossref: 280] [Cited by in F6Publishing: 154] [Article Influence: 31.1] [Reference Citation Analysis]
48 Moskwa P, Buffa FM, Pan Y, Panchakshari R, Gottipati P, Muschel RJ, Beech J, Kulshrestha R, Abdelmohsen K, Weinstock DM. miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors. Mol Cell. 2011;41:210-220. [PMID: 21195000 DOI: 10.1016/j.molcel.2010.12.005] [Cited by in Crossref: 310] [Cited by in F6Publishing: 275] [Article Influence: 28.2] [Reference Citation Analysis]
49 Lehmann BD, Pietenpol JA. Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes. J Pathol. 2014;232:142-150. [PMID: 24114677 DOI: 10.1002/path.4280] [Cited by in Crossref: 227] [Cited by in F6Publishing: 212] [Article Influence: 32.4] [Reference Citation Analysis]
50 Deans AJ, West SC. DNA interstrand crosslink repair and cancer. Nat Rev Cancer 2011;11:467-80. [PMID: 21701511 DOI: 10.1038/nrc3088] [Cited by in Crossref: 632] [Cited by in F6Publishing: 525] [Article Influence: 63.2] [Reference Citation Analysis]
51 Domagala P, Huzarski T, Lubinski J, Gugala K, Domagala W. Immunophenotypic predictive profiling of BRCA1-associated breast cancer. Virchows Arch 2011;458:55-64. [PMID: 20941507 DOI: 10.1007/s00428-010-0988-3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
52 Chabalier-Taste C, Brichese L, Racca C, Canitrot Y, Calsou P, Larminat F. Polo-like kinase 1 mediates BRCA1 phosphorylation and recruitment at DNA double-strand breaks. Oncotarget 2016;7:2269-83. [PMID: 26745677 DOI: 10.18632/oncotarget.6825] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.6] [Reference Citation Analysis]
53 Tassone P, Tagliaferri P, Perricelli A, Blotta S, Quaresima B, Martelli ML, Goel A, Barbieri V, Costanzo F, Boland CR, Venuta S. BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br J Cancer 2003;88:1285-91. [PMID: 12698198 DOI: 10.1038/sj.bjc.6600859] [Cited by in Crossref: 252] [Cited by in F6Publishing: 214] [Article Influence: 14.8] [Reference Citation Analysis]
54 Wilkerson PM, Dedes KJ, Samartzis EP, Dedes I, Lambros MB, Natrajan R, Gauthier A, Piscuoglio S, Töpfer C, Vukovic V, Daley F, Weigelt B, Reis-Filho JS. Preclinical evaluation of the PARP inhibitor BMN-673 for the treatment of ovarian clear cell cancer. Oncotarget 2017;8:6057-66. [PMID: 28002809 DOI: 10.18632/oncotarget.14011] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
55 Perkhofer L, Gout J, Roger E, Kude de Almeida F, Baptista Simões C, Wiesmüller L, Seufferlein T, Kleger A. DNA damage repair as a target in pancreatic cancer: state-of-the-art and future perspectives. Gut 2021;70:606-17. [PMID: 32855305 DOI: 10.1136/gutjnl-2019-319984] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 20.0] [Reference Citation Analysis]
56 Jia Y, Song W, Zhang F, Yan J, Yang Q. Akt1 inhibits homologous recombination in Brca1-deficient cells by blocking the Chk1-Rad51 pathway. Oncogene 2013;32:1943-9. [PMID: 22665067 DOI: 10.1038/onc.2012.211] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
57 Sonoda E, Takata M, Yamashita YM, Morrison C, Takeda S. Homologous DNA recombination in vertebrate cells. Proc Natl Acad Sci U S A 2001;98:8388-94. [PMID: 11459980 DOI: 10.1073/pnas.111006398] [Cited by in Crossref: 97] [Cited by in F6Publishing: 87] [Article Influence: 4.9] [Reference Citation Analysis]
58 Sun X, Cui F, Yin H, Wu D, Wang N, Yuan M, Fei Y, Wang Q. Association between EGFR mutation and expression of BRCA1 and RAP80 in non-small cell lung cancer. Oncol Lett 2018;16:2201-6. [PMID: 30008919 DOI: 10.3892/ol.2018.8938] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
59 Huang F, Mazin AV. A small molecule inhibitor of human RAD51 potentiates breast cancer cell killing by therapeutic agents in mouse xenografts. PLoS One 2014;9:e100993. [PMID: 24971740 DOI: 10.1371/journal.pone.0100993] [Cited by in Crossref: 65] [Cited by in F6Publishing: 54] [Article Influence: 9.3] [Reference Citation Analysis]
60 Wu L, Shao L, Li M, Zheng J, Wang J, Feng W, Chang J, Wang Y, Hauer-Jensen M, Zhou D. BMS-345541 sensitizes MCF-7 breast cancer cells to ionizing radiation by selective inhibition of homologous recombinational repair of DNA double-strand breaks. Radiat Res 2013;179:160-70. [PMID: 23259762 DOI: 10.1667/RR3034.1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
61 Sakai W, Swisher EM, Jacquemont C, Chandramohan KV, Couch FJ, Langdon SP, Wurz K, Higgins J, Villegas E, Taniguchi T. Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma. Cancer Res 2009;69:6381-6. [PMID: 19654294 DOI: 10.1158/0008-5472.CAN-09-1178] [Cited by in Crossref: 201] [Cited by in F6Publishing: 120] [Article Influence: 16.8] [Reference Citation Analysis]
62 Long DT, Joukov V, Budzowska M, Walter JC. BRCA1 promotes unloading of the CMG helicase from a stalled DNA replication fork. Mol Cell 2014;56:174-85. [PMID: 25219499 DOI: 10.1016/j.molcel.2014.08.012] [Cited by in Crossref: 81] [Cited by in F6Publishing: 70] [Article Influence: 11.6] [Reference Citation Analysis]
63 Rowe BP, Glazer PM. Emergence of rationally designed therapeutic strategies for breast cancer targeting DNA repair mechanisms. Breast Cancer Res 2010;12:203. [PMID: 20459590 DOI: 10.1186/bcr2566] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.4] [Reference Citation Analysis]
64 Isakoff SJ. Triple-negative breast cancer: role of specific chemotherapy agents. Cancer J 2010;16:53-61. [PMID: 20164691 DOI: 10.1097/PPO.0b013e3181d24ff7] [Cited by in Crossref: 184] [Cited by in F6Publishing: 104] [Article Influence: 16.7] [Reference Citation Analysis]
65 Cantor SB, Nayak S. FANCJ at the FORK. Mutat Res 2016;788:7-11. [PMID: 26926912 DOI: 10.1016/j.mrfmmm.2016.02.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
66 Patel DS, Misenko SM, Her J, Bunting SF. BLM helicase regulates DNA repair by counteracting RAD51 loading at DNA double-strand break sites. J Cell Biol 2017;216:3521-34. [PMID: 28912125 DOI: 10.1083/jcb.201703144] [Cited by in Crossref: 47] [Cited by in F6Publishing: 37] [Article Influence: 11.8] [Reference Citation Analysis]
67 Gass P, Lux MP, Rauh C, Hein A, Bani MR, Fiessler C, Hartmann A, Häberle L, Pretscher J, Erber R, Wachter DL, Schulz-Wendtland R, Beckmann MW, Fasching PA, Wunderle M. Prediction of pathological complete response and prognosis in patients with neoadjuvant treatment for triple-negative breast cancer. BMC Cancer 2018;18:1051. [PMID: 30373556 DOI: 10.1186/s12885-018-4925-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
68 Morii I, Iwabuchi Y, Mori S, Suekuni M, Natsume T, Yoshida K, Sugimoto N, Kanemaki MT, Fujita M. Inhibiting the MCM8-9 complex selectively sensitizes cancer cells to cisplatin and olaparib. Cancer Sci 2019;110:1044-53. [PMID: 30648820 DOI: 10.1111/cas.13941] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
69 Lebert JM, Lester R, Powell E, Seal M, McCarthy J. Advances in the systemic treatment of triple-negative breast cancer. Curr Oncol 2018;25:S142-50. [PMID: 29910657 DOI: 10.3747/co.25.3954] [Cited by in Crossref: 104] [Cited by in F6Publishing: 84] [Article Influence: 34.7] [Reference Citation Analysis]
70 Yue J, Wang Q, Lu H, Brenneman M, Fan F, Shen Z. The cytoskeleton protein filamin-A is required for an efficient recombinational DNA double strand break repair. Cancer Res 2009;69:7978-85. [PMID: 19808958 DOI: 10.1158/0008-5472.CAN-09-2177] [Cited by in Crossref: 44] [Cited by in F6Publishing: 28] [Article Influence: 3.7] [Reference Citation Analysis]
71 Huen MS, Chen J. Assembly of checkpoint and repair machineries at DNA damage sites. Trends Biochem Sci 2010;35:101-8. [PMID: 19875294 DOI: 10.1016/j.tibs.2009.09.001] [Cited by in Crossref: 85] [Cited by in F6Publishing: 82] [Article Influence: 7.1] [Reference Citation Analysis]
72 Vaklavas C, Forero-Torres A. How do I treat "triple-negative" disease. Curr Treat Options Oncol 2011;12:369-88. [PMID: 22048876 DOI: 10.1007/s11864-011-0168-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
73 Simhadri S, Peterson S, Patel DS, Huo Y, Cai H, Bowman-Colin C, Miller S, Ludwig T, Ganesan S, Bhaumik M, Bunting SF, Jasin M, Xia B. Male fertility defect associated with disrupted BRCA1-PALB2 interaction in mice. J Biol Chem 2014;289:24617-29. [PMID: 25016020 DOI: 10.1074/jbc.M114.566141] [Cited by in Crossref: 43] [Cited by in F6Publishing: 19] [Article Influence: 6.1] [Reference Citation Analysis]
74 Tsvetkova E, Goss GD. Drug resistance and its significance for treatment decisions in non-small-cell lung cancer. Curr Oncol 2012;19:S45-51. [PMID: 22787410 DOI: 10.3747/co.19.1113] [Cited by in Crossref: 22] [Cited by in F6Publishing: 34] [Article Influence: 2.4] [Reference Citation Analysis]
75 Park JY, Zhang F, Andreassen PR. PALB2: the hub of a network of tumor suppressors involved in DNA damage responses. Biochim Biophys Acta 2014;1846:263-75. [PMID: 24998779 DOI: 10.1016/j.bbcan.2014.06.003] [Cited by in Crossref: 18] [Cited by in F6Publishing: 40] [Article Influence: 2.6] [Reference Citation Analysis]
76 McCarthy EE, Celebi JT, Baer R, Ludwig T. Loss of Bard1, the heterodimeric partner of the Brca1 tumor suppressor, results in early embryonic lethality and chromosomal instability. Mol Cell Biol 2003;23:5056-63. [PMID: 12832489 DOI: 10.1128/MCB.23.14.5056-5063.2003] [Cited by in Crossref: 91] [Cited by in F6Publishing: 45] [Article Influence: 5.1] [Reference Citation Analysis]
77 Johnson N, Li YC, Walton ZE, Cheng KA, Li D, Rodig SJ, Moreau LA, Unitt C, Bronson RT, Thomas HD, Newell DR, D'Andrea AD, Curtin NJ, Wong KK, Shapiro GI. Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition. Nat Med 2011;17:875-82. [PMID: 21706030 DOI: 10.1038/nm.2377] [Cited by in Crossref: 180] [Cited by in F6Publishing: 157] [Article Influence: 18.0] [Reference Citation Analysis]
78 Bryant C, Rawlinson R, Massey AJ. Chk1 inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers. BMC Cancer 2014;14:570. [PMID: 25104095 DOI: 10.1186/1471-2407-14-570] [Cited by in Crossref: 62] [Cited by in F6Publishing: 55] [Article Influence: 8.9] [Reference Citation Analysis]
79 Shukla PC, Singh KK, Quan A, Al-Omran M, Teoh H, Lovren F, Cao L, Rovira II, Pan Y, Brezden-Masley C, Yanagawa B, Gupta A, Deng CX, Coles JG, Leong-Poi H, Stanford WL, Parker TG, Schneider MD, Finkel T, Verma S. BRCA1 is an essential regulator of heart function and survival following myocardial infarction. Nat Commun 2011;2:593. [PMID: 22186889 DOI: 10.1038/ncomms1601] [Cited by in Crossref: 83] [Cited by in F6Publishing: 70] [Article Influence: 8.3] [Reference Citation Analysis]
80 Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol 2016;13:674-90. [PMID: 27184417 DOI: 10.1038/nrclinonc.2016.66] [Cited by in Crossref: 903] [Cited by in F6Publishing: 795] [Article Influence: 180.6] [Reference Citation Analysis]
81 Zhang J, Willers H, Feng Z, Ghosh JC, Kim S, Weaver DT, Chung JH, Powell SN, Xia F. Chk2 phosphorylation of BRCA1 regulates DNA double-strand break repair. Mol Cell Biol. 2004;24:708-718. [PMID: 14701743 DOI: 10.1128/MCB.24.2.708-718.2004] [Cited by in Crossref: 205] [Cited by in F6Publishing: 118] [Article Influence: 12.1] [Reference Citation Analysis]
82 Yang ZX, Zhang B, Wei J, Jiang GQ, Wu YL, Leng BJ, Xing CG. MiR-539 inhibits proliferation and migration of triple-negative breast cancer cells by down-regulating LAMA4 expression. Cancer Cell Int 2018;18:16. [PMID: 29434522 DOI: 10.1186/s12935-018-0512-4] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 9.7] [Reference Citation Analysis]
83 Hu Y, Petit SA, Ficarro SB, Toomire KJ, Xie A, Lim E, Cao SA, Park E, Eck MJ, Scully R, Brown M, Marto JA, Livingston DM. PARP1-driven poly-ADP-ribosylation regulates BRCA1 function in homologous recombination-mediated DNA repair. Cancer Discov 2014;4:1430-47. [PMID: 25252691 DOI: 10.1158/2159-8290.CD-13-0891] [Cited by in Crossref: 67] [Cited by in F6Publishing: 52] [Article Influence: 9.6] [Reference Citation Analysis]
84 De Luca P, Vazquez ES, Moiola CP, Zalazar F, Cotignola J, Gueron G, Gardner K, De Siervi A. BRCA1 loss induces GADD153-mediated doxorubicin resistance in prostate cancer. Mol Cancer Res. 2011;9:1078-1090. [PMID: 21700680 DOI: 10.1158/1541-7786.mcr-11-0155] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
85 Foulkes WD, Rosenblatt J, Chappuis PO. The contribution of inherited factors to the clinicopathological features and behavior of breast cancer. J Mammary Gland Biol Neoplasia 2001;6:453-65. [PMID: 12013534 DOI: 10.1023/a:1014791115760] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
86 Garrido-Castro AC, Lin NU, Polyak K. Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment. Cancer Discov 2019;9:176-98. [PMID: 30679171 DOI: 10.1158/2159-8290.CD-18-1177] [Cited by in Crossref: 227] [Cited by in F6Publishing: 134] [Article Influence: 113.5] [Reference Citation Analysis]
87 Urruticoechea A, Archer CD, Assersohn LA, Gregory RK, Verrill M, Mendes R, Walsh G, Smith IE, Johnston SR. Mitomycin C, vinblastine and cisplatin (MVP): an active and well-tolerated salvage regimen for advanced breast cancer. Br J Cancer 2005;92:475-9. [PMID: 15685237 DOI: 10.1038/sj.bjc.6602367] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
88 Bonanno L, Costa C, Majem M, Sanchez JJ, Rodriguez I, Gimenez-Capitan A, Molina-Vila MA, Vergnenegre A, Massuti B, Favaretto A, Rugge M, Pallares C, Taron M, Rosell R. Combinatory effect of BRCA1 and HERC2 expression on outcome in advanced non-small-cell lung cancer. BMC Cancer 2016;16:312. [PMID: 27179511 DOI: 10.1186/s12885-016-2339-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
89 de Groot JS, van Diest PJ, van Amersfoort M, Vlug EJ, Pan X, Ter Hoeve ND, Rosing H, Beijnen JH, Youssef SA, de Bruin A, Jonkers J, van der Wall E, Derksen PWB. Intraductal cisplatin treatment in a BRCA-associated breast cancer mouse model attenuates tumor development but leads to systemic tumors in aged female mice. Oncotarget 2017;8:60750-63. [PMID: 28977823 DOI: 10.18632/oncotarget.18490] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
90 Bayraktar S, Gutierrez-Barrera AM, Liu D, Tasbas T, Akar U, Litton JK, Lin E, Albarracin CT, Meric-Bernstam F, Gonzalez-Angulo AM, Hortobagyi GN, Arun BK. Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations. Breast Cancer Res Treat 2011;130:145-53. [PMID: 21830012 DOI: 10.1007/s10549-011-1711-z] [Cited by in Crossref: 71] [Cited by in F6Publishing: 59] [Article Influence: 7.1] [Reference Citation Analysis]
91 Westermark UK, Reyngold M, Olshen AB, Baer R, Jasin M, Moynahan ME. BARD1 participates with BRCA1 in homology-directed repair of chromosome breaks. Mol Cell Biol. 2003;23:7926-7936. [PMID: 14560035 DOI: 10.1128/MCB.23.21.7926-7936.2003] [Cited by in Crossref: 78] [Cited by in F6Publishing: 46] [Article Influence: 4.3] [Reference Citation Analysis]
92 Nakanoko T, Saeki H, Morita M, Nakashima Y, Ando K, Oki E, Ohga T, Kakeji Y, Toh Y, Maehara Y. Rad51 expression is a useful predictive factor for the efficacy of neoadjuvant chemoradiotherapy in squamous cell carcinoma of the esophagus. Ann Surg Oncol 2014;21:597-604. [PMID: 24065387 DOI: 10.1245/s10434-013-3220-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
93 Candido-dos-Reis FJ, Song H, Goode EL, Cunningham JM, Fridley BL, Larson MC, Alsop K, Dicks E, Harrington P, Ramus SJ, de Fazio A, Mitchell G, Fereday S, Bolton KL, Gourley C, Michie C, Karlan B, Lester J, Walsh C, Cass I, Olsson H, Gore M, Benitez JJ, Garcia MJ, Andrulis I, Mulligan AM, Glendon G, Blanco I, Lazaro C, Whittemore AS, McGuire V, Sieh W, Montagna M, Alducci E, Sadetzki S, Chetrit A, Kwong A, Kjaer SK, Jensen A, Høgdall E, Neuhausen S, Nussbaum R, Daly M, Greene MH, Mai PL, Loud JT, Moysich K, Toland AE, Lambrechts D, Ellis S, Frost D, Brenton JD, Tischkowitz M, Easton DF, Antoniou A, Chenevix-Trench G, Gayther SA, Bowtell D, Pharoah PD; for EMBRACE., kConFab Investigators., Australian Ovarian Cancer Study Group. Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer. Clin Cancer Res 2015;21:652-7. [PMID: 25398451 DOI: 10.1158/1078-0432.CCR-14-2497] [Cited by in Crossref: 89] [Cited by in F6Publishing: 45] [Article Influence: 12.7] [Reference Citation Analysis]
94 Price M, Monteiro AN. Fine tuning chemotherapy to match BRCA1 status. Biochem Pharmacol 2010;80:647-53. [PMID: 20510205 DOI: 10.1016/j.bcp.2010.05.015] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
95 O'Byrne KJ, Barr MP, Gray SG. The role of epigenetics in resistance to Cisplatin chemotherapy in lung cancer. Cancers (Basel) 2011;3:1426-53. [PMID: 24212667 DOI: 10.3390/cancers3011426] [Cited by in Crossref: 28] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
96 Heijink AM, Everts M, Honeywell ME, Richards R, Kok YP, de Vries EGE, Lee MJ, van Vugt MATM. Modeling of Cisplatin-Induced Signaling Dynamics in Triple-Negative Breast Cancer Cells Reveals Mediators of Sensitivity. Cell Rep 2019;28:2345-2357.e5. [PMID: 31461651 DOI: 10.1016/j.celrep.2019.07.070] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
97 Roy V, Pockaj BA, Allred JB, Apsey H, Northfelt DW, Nikcevich D, Mattar B, Perez EA. A Phase II trial of docetaxel and carboplatin administered every 2 weeks as preoperative therapy for stage II or III breast cancer: NCCTG study N0338. Am J Clin Oncol 2013;36:540-4. [PMID: 22868240 DOI: 10.1097/COC.0b013e318256f619] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
98 Sakai W, Swisher EM, Karlan BY, Agarwal MK, Higgins J, Friedman C, Villegas E, Jacquemont C, Farrugia DJ, Couch FJ. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature. 2008;451:1116-1120. [PMID: 18264087 DOI: 10.1038/nature06633] [Cited by in Crossref: 656] [Cited by in F6Publishing: 563] [Article Influence: 50.5] [Reference Citation Analysis]
99 Callen E, Di Virgilio M, Kruhlak MJ, Nieto-Soler M, Wong N, Chen HT, Faryabi RB, Polato F, Santos M, Starnes LM, Wesemann DR, Lee JE, Tubbs A, Sleckman BP, Daniel JA, Ge K, Alt FW, Fernandez-Capetillo O, Nussenzweig MC, Nussenzweig A. 53BP1 mediates productive and mutagenic DNA repair through distinct phosphoprotein interactions. Cell 2013;153:1266-80. [PMID: 23727112 DOI: 10.1016/j.cell.2013.05.023] [Cited by in Crossref: 227] [Cited by in F6Publishing: 203] [Article Influence: 28.4] [Reference Citation Analysis]
100 Lai D, Visser-Grieve S, Yang X. Tumour suppressor genes in chemotherapeutic drug response. Biosci Rep 2012;32:361-74. [PMID: 22762204 DOI: 10.1042/BSR20110125] [Cited by in Crossref: 53] [Cited by in F6Publishing: 29] [Article Influence: 5.9] [Reference Citation Analysis]
101 Alli E, Sharma VB, Hartman AR, Lin PS, McPherson L, Ford JM. Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells. BMC Pharmacol 2011;11:7. [PMID: 21771338 DOI: 10.1186/1471-2210-11-7] [Cited by in Crossref: 29] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
102 Tung NM, Garber JE. BRCA1/2 testing: therapeutic implications for breast cancer management. Br J Cancer 2018;119:141-52. [PMID: 29867226 DOI: 10.1038/s41416-018-0127-5] [Cited by in Crossref: 69] [Cited by in F6Publishing: 50] [Article Influence: 23.0] [Reference Citation Analysis]
103 Imyanitov EN, Moiseyenko VM. Drug therapy for hereditary cancers. Hered Cancer Clin Pract 2011;9:5. [PMID: 21819606 DOI: 10.1186/1897-4287-9-5] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
104 Hastak K, Alli E, Ford JM. Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin. Cancer Res. 2010;70:7970-7980. [PMID: 20798217 DOI: 10.1158/0008-5472.can-09-4521] [Cited by in Crossref: 114] [Cited by in F6Publishing: 68] [Article Influence: 10.4] [Reference Citation Analysis]
105 Dhillon KK, Swisher EM, Taniguchi T. Secondary mutations of BRCA1/2 and drug resistance. Cancer Sci 2011;102:663-9. [PMID: 21205087 DOI: 10.1111/j.1349-7006.2010.01840.x] [Cited by in Crossref: 82] [Cited by in F6Publishing: 72] [Article Influence: 8.2] [Reference Citation Analysis]
106 Chan DA, Giaccia AJ. Harnessing synthetic lethal interactions in anticancer drug discovery. Nat Rev Drug Discov 2011;10:351-64. [PMID: 21532565 DOI: 10.1038/nrd3374] [Cited by in Crossref: 194] [Cited by in F6Publishing: 162] [Article Influence: 19.4] [Reference Citation Analysis]
107 Comen EA, Robson M. Poly (ADP-ribose) polymerase inhibitors in triple-negative breast cancer. Cancer J. 2010;16:48-52. [PMID: 20164690 DOI: 10.1097/ppo.0b013e3181cf01eb] [Cited by in Crossref: 33] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
108 Jin J, Zhang W, Ji W, Yang F, Guan X. Predictive biomarkers for triple negative breast cancer treated with platinum-based chemotherapy. Cancer Biol Ther 2017;18:369-78. [PMID: 28494179 DOI: 10.1080/15384047.2017.1323582] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
109 Draga M, Madgett EB, Vandenberg CJ, du Plessis D, Kaufmann A, Werler P, Chakraborty P, Lowndes NF, Hiom K. BRCA1 Is Required for Maintenance of Phospho-Chk1 and G2/M Arrest during DNA Cross-Link Repair in DT40 Cells. Mol Cell Biol 2015;35:3829-40. [PMID: 26324327 DOI: 10.1128/MCB.01497-14] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
110 Yu YM, Pace SM, Allen SR, Deng CX, Hsu LC. A PP1-binding motif present in BRCA1 plays a role in its DNA repair function. Int J Biol Sci 2008;4:352-61. [PMID: 18953404 DOI: 10.7150/ijbs.4.352] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
111 Hoadley KA, Weigman VJ, Fan C, Sawyer LR, He X, Troester MA, Sartor CI, Rieger-House T, Bernard PS, Carey LA. EGFR associated expression profiles vary with breast tumor subtype. BMC Genomics. 2007;8:258. [PMID: 17663798 DOI: 10.1186/1471-2164-8-258] [Cited by in Crossref: 198] [Cited by in F6Publishing: 176] [Article Influence: 14.1] [Reference Citation Analysis]
112 Bunting SF, Callén E, Wong N, Chen HT, Polato F, Gunn A, Bothmer A, Feldhahn N, Fernandez-Capetillo O, Cao L, Xu X, Deng CX, Finkel T, Nussenzweig M, Stark JM, Nussenzweig A. 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. Cell 2010;141:243-54. [PMID: 20362325 DOI: 10.1016/j.cell.2010.03.012] [Cited by in Crossref: 1054] [Cited by in F6Publishing: 932] [Article Influence: 95.8] [Reference Citation Analysis]
113 Casero RA Jr, Woster PM. Recent advances in the development of polyamine analogues as antitumor agents. J Med Chem 2009;52:4551-73. [PMID: 19534534 DOI: 10.1021/jm900187v] [Cited by in Crossref: 123] [Cited by in F6Publishing: 86] [Article Influence: 10.3] [Reference Citation Analysis]
114 Nakamura K, Kogame T, Oshiumi H, Shinohara A, Sumitomo Y, Agama K, Pommier Y, Tsutsui KM, Tsutsui K, Hartsuiker E, Ogi T, Takeda S, Taniguchi Y. Collaborative action of Brca1 and CtIP in elimination of covalent modifications from double-strand breaks to facilitate subsequent break repair. PLoS Genet 2010;6:e1000828. [PMID: 20107609 DOI: 10.1371/journal.pgen.1000828] [Cited by in Crossref: 108] [Cited by in F6Publishing: 96] [Article Influence: 9.8] [Reference Citation Analysis]
115 Lin ZP, Zhu YL, Ratner ES. Targeting Cyclin-Dependent Kinases for Treatment of Gynecologic Cancers. Front Oncol 2018;8:303. [PMID: 30135856 DOI: 10.3389/fonc.2018.00303] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 7.7] [Reference Citation Analysis]
116 Holanek M, Selingerova I, Bilek O, Kazda T, Fabian P, Foretova L, Zvarikova M, Obermannova R, Kolouskova I, Coufal O, Petrakova K, Svoboda M, Poprach A. Neoadjuvant Chemotherapy of Triple-Negative Breast Cancer: Evaluation of Early Clinical Response, Pathological Complete Response Rates, and Addition of Platinum Salts Benefit Based on Real-World Evidence. Cancers (Basel) 2021;13:1586. [PMID: 33808149 DOI: 10.3390/cancers13071586] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
117 Swisher EM, Sakai W, Karlan BY, Wurz K, Urban N, Taniguchi T. Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res. 2008;68:2581-2586. [PMID: 18413725 DOI: 10.1158/0008-5472.can-08-0088] [Cited by in Crossref: 331] [Cited by in F6Publishing: 170] [Article Influence: 25.5] [Reference Citation Analysis]
118 Pouptsis A, Swafe L, Patwardhan M, Stavraka C. Surgical and Systemic Treatment of Hereditary Breast Cancer: A Mini-Review With a Focus on BRCA1 and BRCA2 Mutations. Front Oncol 2020;10:553080. [PMID: 33194613 DOI: 10.3389/fonc.2020.553080] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
119 Pennisi R, Ascenzi P, di Masi A. Hsp90: A New Player in DNA Repair? Biomolecules 2015;5:2589-618. [PMID: 26501335 DOI: 10.3390/biom5042589] [Cited by in Crossref: 55] [Cited by in F6Publishing: 52] [Article Influence: 9.2] [Reference Citation Analysis]
120 Wang S, Scharadin TM, Zimmermann M, Malfatti MA, Turteltaub KW, de Vere White R, Pan CX, Henderson PT. Correlation of Platinum Cytotoxicity to Drug-DNA Adduct Levels in a Breast Cancer Cell Line Panel. Chem Res Toxicol 2018;31:1293-304. [PMID: 30381944 DOI: 10.1021/acs.chemrestox.8b00170] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
121 Reid LJ, Shakya R, Modi AP, Lokshin M, Cheng JT, Jasin M, Baer R, Ludwig T. E3 ligase activity of BRCA1 is not essential for mammalian cell viability or homology-directed repair of double-strand DNA breaks. Proc Natl Acad Sci U S A 2008;105:20876-81. [PMID: 19088202 DOI: 10.1073/pnas.0811203106] [Cited by in Crossref: 90] [Cited by in F6Publishing: 87] [Article Influence: 6.9] [Reference Citation Analysis]
122 Longerich S, Orelli BJ, Martin RW, Bishop DK, Storb U. Brca1 in immunoglobulin gene conversion and somatic hypermutation. DNA Repair (Amst) 2008;7:253-66. [PMID: 18036997 DOI: 10.1016/j.dnarep.2007.10.002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
123 Rigakos G, Razis E. BRCAness: finding the Achilles heel in ovarian cancer. Oncologist 2012;17:956-62. [PMID: 22673632 DOI: 10.1634/theoncologist.2012-0028] [Cited by in Crossref: 66] [Cited by in F6Publishing: 62] [Article Influence: 7.3] [Reference Citation Analysis]
124 Reddy KB. Triple-negative breast cancers: an updated review on treatment options. Curr Oncol 2011;18:e173-9. [PMID: 21874107 DOI: 10.3747/co.v18i4.738] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 4.5] [Reference Citation Analysis]
125 Shafee N, Smith CR, Wei S, Kim Y, Mills GB, Hortobagyi GN, Stanbridge EJ, Lee EY. Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors. Cancer Res. 2008;68:3243-3250. [PMID: 18451150 DOI: 10.1158/0008-5472.can-07-5480] [Cited by in Crossref: 211] [Cited by in F6Publishing: 123] [Article Influence: 16.2] [Reference Citation Analysis]
126 Helchowski CM, Skow LF, Roberts KH, Chute CL, Canman CE. A small ubiquitin binding domain inhibits ubiquitin-dependent protein recruitment to DNA repair foci. Cell Cycle 2013;12:3749-58. [PMID: 24107634 DOI: 10.4161/cc.26640] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
127 Lin ZP, Lee Y, Lin F, Belcourt MF, Li P, Cory JG, Glazer PM, Sartorelli AC. Reduced level of ribonucleotide reductase R2 subunits increases dependence on homologous recombination repair of cisplatin-induced DNA damage. Mol Pharmacol 2011;80:1000-12. [PMID: 21875941 DOI: 10.1124/mol.111.074708] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
128 Rosell R, Perez-Roca L, Sanchez JJ, Cobo M, Moran T, Chaib I, Provencio M, Domine M, Sala MA, Jimenez U, Diz P, Barneto I, Macias JA, de Las Peñas R, Catot S, Isla D, Sanchez JM, Ibeas R, Lopez-Vivanco G, Oramas J, Mendez P, Reguart N, Blanco R, Taron M. Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression. PLoS One 2009;4:e5133. [PMID: 19415121 DOI: 10.1371/journal.pone.0005133] [Cited by in Crossref: 120] [Cited by in F6Publishing: 94] [Article Influence: 10.0] [Reference Citation Analysis]
129 Dias MP, Moser SC, Ganesan S, Jonkers J. Understanding and overcoming resistance to PARP inhibitors in cancer therapy. Nat Rev Clin Oncol 2021. [PMID: 34285417 DOI: 10.1038/s41571-021-00532-x] [Reference Citation Analysis]
130 Broering TJ, Alavattam KG, Sadreyev RI, Ichijima Y, Kato Y, Hasegawa K, Camerini-Otero RD, Lee JT, Andreassen PR, Namekawa SH. BRCA1 establishes DNA damage signaling and pericentric heterochromatin of the X chromosome in male meiosis. J Cell Biol 2014;205:663-75. [PMID: 24914237 DOI: 10.1083/jcb.201311050] [Cited by in Crossref: 45] [Cited by in F6Publishing: 32] [Article Influence: 6.4] [Reference Citation Analysis]
131 Park D, Shakya R, Koivisto C, Pitarresi JR, Szabolcs M, Kladney R, Hadjis A, Mace TA, Ludwig T. Murine models for familial pancreatic cancer: Histopathology, latency and drug sensitivity among cancers of Palb2, Brca1 and Brca2 mutant mouse strains. PLoS One 2019;14:e0226714. [PMID: 31877165 DOI: 10.1371/journal.pone.0226714] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
132 Sun C, Li N, Ding D, Weng D, Meng L, Chen G, Ma D. The role of BRCA status on the prognosis of patients with epithelial ovarian cancer: a systematic review of the literature with a meta-analysis. PLoS One. 2014;9:e95285. [PMID: 24788697 DOI: 10.1371/journal.pone.0095285] [Cited by in Crossref: 51] [Cited by in F6Publishing: 47] [Article Influence: 7.3] [Reference Citation Analysis]
133 Qing Y, Yamazoe M, Hirota K, Dejsuphong D, Sakai W, Yamamoto KN, Bishop DK, Wu X, Takeda S. The epistatic relationship between BRCA2 and the other RAD51 mediators in homologous recombination. PLoS Genet 2011;7:e1002148. [PMID: 21779174 DOI: 10.1371/journal.pgen.1002148] [Cited by in Crossref: 48] [Cited by in F6Publishing: 47] [Article Influence: 4.8] [Reference Citation Analysis]
134 Gasior SL, Olivares H, Ear U, Hari DM, Weichselbaum R, Bishop DK. Assembly of RecA-like recombinases: distinct roles for mediator proteins in mitosis and meiosis. Proc Natl Acad Sci U S A 2001;98:8411-8. [PMID: 11459983 DOI: 10.1073/pnas.121046198] [Cited by in Crossref: 104] [Cited by in F6Publishing: 113] [Article Influence: 5.2] [Reference Citation Analysis]
135 Zoeller JJ, Vagodny A, Daniels VW, Taneja K, Tan BY, DeRose YS, Fujita M, Welm AL, Letai A, Leverson JD, Blot V, Bronson RT, Dillon DA, Brugge JS. Navitoclax enhances the effectiveness of EGFR-targeted antibody-drug conjugates in PDX models of EGFR-expressing triple-negative breast cancer. Breast Cancer Res 2020;22:132. [PMID: 33256808 DOI: 10.1186/s13058-020-01374-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
136 Kraakman-van der Zwet M, Overkamp WJ, van Lange RE, Essers J, van Duijn-Goedhart A, Wiggers I, Swaminathan S, van Buul PP, Errami A, Tan RT, Jaspers NG, Sharan SK, Kanaar R, Zdzienicka MZ. Brca2 (XRCC11) deficiency results in radioresistant DNA synthesis and a higher frequency of spontaneous deletions. Mol Cell Biol 2002;22:669-79. [PMID: 11756561 DOI: 10.1128/MCB.22.2.669-679.2002] [Cited by in Crossref: 177] [Cited by in F6Publishing: 80] [Article Influence: 9.3] [Reference Citation Analysis]
137 Bassey-Archibong BI, Rayner LG, Hercules SM, Aarts CW, Dvorkin-Gheva A, Bramson JL, Hassell JA, Daniel JM. Kaiso depletion attenuates the growth and survival of triple negative breast cancer cells. Cell Death Dis 2017;8:e2689. [PMID: 28333150 DOI: 10.1038/cddis.2017.92] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
138 Zhao W, Wiese C, Kwon Y, Hromas R, Sung P. The BRCA Tumor Suppressor Network in Chromosome Damage Repair by Homologous Recombination. Annu Rev Biochem 2019;88:221-45. [PMID: 30917004 DOI: 10.1146/annurev-biochem-013118-111058] [Cited by in Crossref: 42] [Cited by in F6Publishing: 33] [Article Influence: 21.0] [Reference Citation Analysis]
139 Mason JM, Sekiguchi JM. Snm1B/Apollo functions in the Fanconi anemia pathway in response to DNA interstrand crosslinks. Hum Mol Genet 2011;20:2549-59. [PMID: 21478198 DOI: 10.1093/hmg/ddr153] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
140 Bao K, Li Y, Wei J, Li R, Yang J, Shi J, Li B, Zhu J, Mao F, Jia R, Li J. Fangchinoline suppresses conjunctival melanoma by directly binding FUBP2 and inhibiting the homologous recombination pathway. Cell Death Dis 2021;12:380. [PMID: 33828201 DOI: 10.1038/s41419-021-03653-4] [Reference Citation Analysis]
141 Bouwman P, Aly A, Escandell JM, Pieterse M, Bartkova J, van der Gulden H, Hiddingh S, Thanasoula M, Kulkarni A, Yang Q, Haffty BG, Tommiska J, Blomqvist C, Drapkin R, Adams DJ, Nevanlinna H, Bartek J, Tarsounas M, Ganesan S, Jonkers J. 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nat Struct Mol Biol 2010;17:688-95. [PMID: 20453858 DOI: 10.1038/nsmb.1831] [Cited by in Crossref: 635] [Cited by in F6Publishing: 564] [Article Influence: 57.7] [Reference Citation Analysis]
142 Foulkes WD. BRCA1 and BRCA2: chemosensitivity, treatment outcomes and prognosis. Fam Cancer 2006;5:135-42. [PMID: 16736282 DOI: 10.1007/s10689-005-2832-5] [Cited by in Crossref: 100] [Cited by in F6Publishing: 78] [Article Influence: 6.7] [Reference Citation Analysis]
143 Hassan R, Morrow B, Thomas A, Walsh T, Lee MK, Gulsuner S, Gadiraju M, Panou V, Gao S, Mian I, Khan J, Raffeld M, Patel S, Xi L, Wei JS, Hesdorffer M, Zhang J, Calzone K, Desai A, Padiernos E, Alewine C, Schrump DS, Steinberg SM, Kindler HL, King MC, Churpek JE. Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy. Proc Natl Acad Sci U S A. 2019;116:9008-9013. [PMID: 30975761 DOI: 10.1073/pnas.1821510116] [Cited by in Crossref: 49] [Cited by in F6Publishing: 41] [Article Influence: 24.5] [Reference Citation Analysis]
144 Yamamoto Y, Iwase H. Clinicopathological features and treatment strategy for triple-negative breast cancer. Int J Clin Oncol 2010;15:341-51. [PMID: 20632057 DOI: 10.1007/s10147-010-0106-1] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 2.6] [Reference Citation Analysis]
145 Huen MS, Sy SM, Chen J. BRCA1 and its toolbox for the maintenance of genome integrity. Nat Rev Mol Cell Biol 2010;11:138-48. [PMID: 20029420 DOI: 10.1038/nrm2831] [Cited by in Crossref: 318] [Cited by in F6Publishing: 305] [Article Influence: 26.5] [Reference Citation Analysis]
146 Norquist B, Wurz KA, Pennil CC, Garcia R, Gross J, Sakai W, Karlan BY, Taniguchi T, Swisher EM. Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J Clin Oncol 2011;29:3008-15. [PMID: 21709188 DOI: 10.1200/JCO.2010.34.2980] [Cited by in Crossref: 365] [Cited by in F6Publishing: 208] [Article Influence: 36.5] [Reference Citation Analysis]
147 Hartman AR, Ford JM. BRCA1 and p53: compensatory roles in DNA repair. J Mol Med (Berl) 2003;81:700-7. [PMID: 13679996 DOI: 10.1007/s00109-003-0477-0] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 1.7] [Reference Citation Analysis]
148 Lin YH, Yuan J, Pei H, Liu T, Ann DK, Lou Z. KAP1 Deacetylation by SIRT1 Promotes Non-Homologous End-Joining Repair. PLoS One 2015;10:e0123935. [PMID: 25905708 DOI: 10.1371/journal.pone.0123935] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
149 Feng Y, Li X, Cassady K, Zou Z, Zhang X. TET2 Function in Hematopoietic Malignancies, Immune Regulation, and DNA Repair. Front Oncol 2019;9:210. [PMID: 31001476 DOI: 10.3389/fonc.2019.00210] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 18.0] [Reference Citation Analysis]
150 Claybon A, Karia B, Bruce C, Bishop AJ. PARP1 suppresses homologous recombination events in mice in vivo. Nucleic Acids Res 2010;38:7538-45. [PMID: 20660013 DOI: 10.1093/nar/gkq624] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
151 Piscitello D, Varshney D, Lilla S, Vizioli MG, Reid C, Gorbunova V, Seluanov A, Gillespie DA, Adams PD. AKT overactivation can suppress DNA repair via p70S6 kinase-dependent downregulation of MRE11. Oncogene 2018;37:427-38. [PMID: 28967905 DOI: 10.1038/onc.2017.340] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
152 Xie Y, Jiang Y, Yang XB, Wang AQ, Zheng YC, Wan XS, Sang XT, Wang K, Zhang DD, Xu JJ, Li FG, Zhao HT. Response of BRCA1-mutated gallbladder cancer to olaparib: A case report. World J Gastroenterol 2016;22:10254-9. [PMID: 28028375 DOI: 10.3748/wjg.v22.i46.10254] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
153 Bonanno L, Costa C, Majem M, Sanchez JJ, Gimenez-Capitan A, Rodriguez I, Vergnenegre A, Massuti B, Favaretto A, Rugge M, Pallares C, Taron M, Rosell R. The predictive value of 53BP1 and BRCA1 mRNA expression in advanced non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy. Oncotarget 2013;4:1572-81. [PMID: 24197907 DOI: 10.18632/oncotarget.1157] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
154 Drew Y. The development of PARP inhibitors in ovarian cancer: from bench to bedside. Br J Cancer 2015;113 Suppl 1:S3-9. [PMID: 26669452 DOI: 10.1038/bjc.2015.394] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 6.4] [Reference Citation Analysis]
155 Williams HL, Gottesman ME, Gautier J. The differences between ICL repair during and outside of S phase. Trends Biochem Sci 2013;38:386-93. [PMID: 23830640 DOI: 10.1016/j.tibs.2013.05.004] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
156 Cruz C, Castroviejo-Bermejo M, Gutiérrez-Enríquez S, Llop-Guevara A, Ibrahim YH, Gris-Oliver A, Bonache S, Morancho B, Bruna A, Rueda OM, Lai Z, Polanska UM, Jones GN, Kristel P, de Bustos L, Guzman M, Rodríguez O, Grueso J, Montalban G, Caratú G, Mancuso F, Fasani R, Jiménez J, Howat WJ, Dougherty B, Vivancos A, Nuciforo P, Serres-Créixams X, Rubio IT, Oaknin A, Cadogan E, Barrett JC, Caldas C, Baselga J, Saura C, Cortés J, Arribas J, Jonkers J, Díez O, O'Connor MJ, Balmaña J, Serra V. RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer. Ann Oncol 2018;29:1203-10. [PMID: 29635390 DOI: 10.1093/annonc/mdy099] [Cited by in Crossref: 123] [Cited by in F6Publishing: 89] [Article Influence: 61.5] [Reference Citation Analysis]
157 Ratner ES, Sartorelli AC, Lin ZP. Poly (ADP-ribose) polymerase inhibitors: on the horizon of tailored and personalized therapies for epithelial ovarian cancer. Curr Opin Oncol 2012;24:564-71. [PMID: 22759740 DOI: 10.1097/CCO.0b013e3283564230] [Cited by in Crossref: 34] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
158 Nilles N, Fahrenkrog B. Taking a Bad Turn: Compromised DNA Damage Response in Leukemia. Cells 2017;6:E11. [PMID: 28471392 DOI: 10.3390/cells6020011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
159 Gucalp A, Traina TA. Triple-negative breast cancer: adjuvant therapeutic options. Chemother Res Pract 2011;2011:696208. [PMID: 22312556 DOI: 10.1155/2011/696208] [Cited by in Crossref: 18] [Cited by in F6Publishing: 33] [Article Influence: 1.8] [Reference Citation Analysis]
160 Fouad S, Wells OS, Hill MA, D'Angiolella V. Cullin Ring Ubiquitin Ligases (CRLs) in Cancer: Responses to Ionizing Radiation (IR) Treatment. Front Physiol 2019;10:1144. [PMID: 31632280 DOI: 10.3389/fphys.2019.01144] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
161 Xu X, Chen E, Mo L, Zhang L, Shao F, Miao K, Liu J, Su SM, Valecha M, Chan UI, Zheng H, Chen M, Chen W, Chen Q, Fu H, Aladjem MI, He Y, Deng CX. BRCA1 represses DNA replication initiation through antagonizing estrogen signaling and maintains genome stability in parallel with WEE1-MCM2 signaling during pregnancy. Hum Mol Genet 2019;28:842-57. [PMID: 30445628 DOI: 10.1093/hmg/ddy398] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
162 Arun B, Bayraktar S, Liu DD, Gutierrez Barrera AM, Atchley D, Pusztai L, Litton JK, Valero V, Meric-Bernstam F, Hortobagyi GN, Albarracin C. Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience. J Clin Oncol 2011;29:3739-46. [PMID: 21900106 DOI: 10.1200/JCO.2011.35.2682] [Cited by in Crossref: 113] [Cited by in F6Publishing: 47] [Article Influence: 11.3] [Reference Citation Analysis]
163 Adamo A, Montemauri P, Silva N, Ward JD, Boulton SJ, La Volpe A. BRC-1 acts in the inter-sister pathway of meiotic double-strand break repair. EMBO Rep 2008;9:287-92. [PMID: 18219312 DOI: 10.1038/sj.embor.7401167] [Cited by in Crossref: 65] [Cited by in F6Publishing: 52] [Article Influence: 5.0] [Reference Citation Analysis]
164 Swisher EM, Gonzalez RM, Taniguchi T, Garcia RL, Walsh T, Goff BA, Welcsh P. Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas. Mol Cancer. 2009;8:48. [PMID: 19602291 DOI: 10.1186/1476-4598-8-48] [Cited by in Crossref: 76] [Cited by in F6Publishing: 63] [Article Influence: 6.3] [Reference Citation Analysis]
165 Grotsky DA, Gonzalez-Suarez I, Novell A, Neumann MA, Yaddanapudi SC, Croke M, Martinez-Alonso M, Redwood AB, Ortega-Martinez S, Feng Z, Lerma E, Ramon y Cajal T, Zhang J, Matias-Guiu X, Dusso A, Gonzalo S. BRCA1 loss activates cathepsin L-mediated degradation of 53BP1 in breast cancer cells. J Cell Biol 2013;200:187-202. [PMID: 23337117 DOI: 10.1083/jcb.201204053] [Cited by in Crossref: 54] [Cited by in F6Publishing: 47] [Article Influence: 6.8] [Reference Citation Analysis]
166 Bowen RL, Duffy SW, Ryan DA, Hart IR, Jones JL. Early onset of breast cancer in a group of British black women. Br J Cancer 2008;98:277-81. [PMID: 18182985 DOI: 10.1038/sj.bjc.6604174] [Cited by in Crossref: 98] [Cited by in F6Publishing: 85] [Article Influence: 7.5] [Reference Citation Analysis]
167 Christou CM, Kyriacou K. BRCA1 and Its Network of Interacting Partners. Biology (Basel) 2013;2:40-63. [PMID: 24832651 DOI: 10.3390/biology2010040] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
168 Chakraborty P, Hiom K. DHX9-dependent recruitment of BRCA1 to RNA promotes DNA end resection in homologous recombination. Nat Commun 2021;12:4126. [PMID: 34226554 DOI: 10.1038/s41467-021-24341-z] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
169 Kotian S, Banerjee T, Lockhart A, Huang K, Catalyurek UV, Parvin JD. NUSAP1 influences the DNA damage response by controlling BRCA1 protein levels. Cancer Biol Ther 2014;15:533-43. [PMID: 24521615 DOI: 10.4161/cbt.28019] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
170 Liu N. XRCC2 is Required for the Formation of Rad51 Foci Induced by Ionizing Radiation and DNA Cross-Linking Agent Mitomycin C. J Biomed Biotechnol 2002;2:106-13. [PMID: 12488590 DOI: 10.1155/S1110724302204040] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
171 Clark O, Botrel TE, Paladini L, Ferreira MB. Targeted therapy in triple-negative metastatic breast cancer: a systematic review and meta-analysis. Core Evid 2014;9:1-11. [PMID: 24476748 DOI: 10.2147/CE.S52197] [Cited by in Crossref: 26] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
172 Lisby M, Rothstein R. Choreography of recombination proteins during the DNA damage response. DNA Repair (Amst) 2009;8:1068-76. [PMID: 19473884 DOI: 10.1016/j.dnarep.2009.04.007] [Cited by in Crossref: 87] [Cited by in F6Publishing: 81] [Article Influence: 7.3] [Reference Citation Analysis]
173 Levallet G, Dubois F, Fouret P, Antoine M, Brosseau S, Bergot E, Beau-Faller M, Gounant V, Brambilla E, Debieuvre D, Molinier O, Galateau-Sallé F, Mazieres J, Quoix E, Pujol JL, Moro-Sibilot D, Langlais A, Morin F, Westeel V, Zalcman G. MSH2/BRCA1 expression as a DNA-repair signature predicting survival in early-stage lung cancer patients from the IFCT-0002 Phase 3 Trial. Oncotarget 2017;8:4313-29. [PMID: 28008145 DOI: 10.18632/oncotarget.14025] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
174 Xie J, Litman R, Wang S, Peng M, Guillemette S, Rooney T, Cantor SB. Targeting the FANCJ-BRCA1 interaction promotes a switch from recombination to poleta-dependent bypass. Oncogene 2010;29:2499-508. [PMID: 20173781 DOI: 10.1038/onc.2010.18] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 4.5] [Reference Citation Analysis]
175 Stecklein SR, Kumaraswamy E, Behbod F, Wang W, Chaguturu V, Harlan-Williams LM, Jensen RA. BRCA1 and HSP90 cooperate in homologous and non-homologous DNA double-strand-break repair and G2/M checkpoint activation. Proc Natl Acad Sci U S A 2012;109:13650-5. [PMID: 22869732 DOI: 10.1073/pnas.1203326109] [Cited by in Crossref: 81] [Cited by in F6Publishing: 78] [Article Influence: 9.0] [Reference Citation Analysis]
176 Saeki H, Nakashima Y, Zaitsu Y, Tsuda Y, Kasagi Y, Ando K, Imamura Y, Ohgaki K, Ito S, Kimura Y, Egashira A, Oki E, Morita M, Maehara Y. Current status of and perspectives regarding neoadjuvant chemoradiotherapy for locally advanced esophageal squamous cell carcinoma. Surg Today 2016;46:261-7. [PMID: 25740123 DOI: 10.1007/s00595-015-1144-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
177 Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121:2750-2767. [PMID: 21633166 DOI: 10.1172/jci45014] [Cited by in Crossref: 2695] [Cited by in F6Publishing: 1679] [Article Influence: 269.5] [Reference Citation Analysis]
178 Mayer IA, Abramson VG, Lehmann BD, Pietenpol JA. New strategies for triple-negative breast cancer--deciphering the heterogeneity. Clin Cancer Res. 2014;20:782-790. [PMID: 24536073 DOI: 10.1158/1078-0432.ccr-13-0583] [Cited by in Crossref: 186] [Cited by in F6Publishing: 115] [Article Influence: 26.6] [Reference Citation Analysis]
179 Bonanno L, Favaretto A, Rugge M, Taron M, Rosell R. Role of genotyping in non-small cell lung cancer treatment: current status. Drugs 2011;71:2231-46. [PMID: 22085382 DOI: 10.2165/11597700-000000000-00000] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
180 Zimmermann M, de Lange T. 53BP1: pro choice in DNA repair. Trends Cell Biol 2014;24:108-17. [PMID: 24094932 DOI: 10.1016/j.tcb.2013.09.003] [Cited by in Crossref: 226] [Cited by in F6Publishing: 194] [Article Influence: 28.3] [Reference Citation Analysis]
181 Huang YW. Association of BRCA1/2 mutations with ovarian cancer prognosis: An updated meta-analysis. Medicine (Baltimore) 2018;97:e9380. [PMID: 29480828 DOI: 10.1097/MD.0000000000009380] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
182 Cooke SL, Ng CK, Melnyk N, Garcia MJ, Hardcastle T, Temple J, Langdon S, Huntsman D, Brenton JD. Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma. Oncogene 2010;29:4905-13. [PMID: 20581869 DOI: 10.1038/onc.2010.245] [Cited by in Crossref: 114] [Cited by in F6Publishing: 98] [Article Influence: 10.4] [Reference Citation Analysis]
183 Jiang J, Lu Y, Li Z, Li L, Niu D, Xu W, Liu J, Fu L, Zhou Z, Gu Y, Xia F. Ganetespib overcomes resistance to PARP inhibitors in breast cancer by targeting core proteins in the DNA repair machinery. Invest New Drugs 2017;35:251-9. [PMID: 28111726 DOI: 10.1007/s10637-016-0424-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
184 Villamar Cruz O, Prudnikova TY, Araiza-Olivera D, Perez-Plasencia C, Johnson N, Bernhardy AJ, Slifker M, Renner C, Chernoff J, Arias-Romero LE. Reduced PAK1 activity sensitizes FA/BRCA-proficient breast cancer cells to PARP inhibition. Oncotarget 2016;7:76590-603. [PMID: 27740936 DOI: 10.18632/oncotarget.12576] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
185 Skvarova Kramarzova K, Osborn MJ, Webber BR, DeFeo AP, McElroy AN, Kim CJ, Tolar J. CRISPR/Cas9-Mediated Correction of the FANCD1 Gene in Primary Patient Cells. Int J Mol Sci 2017;18:E1269. [PMID: 28613254 DOI: 10.3390/ijms18061269] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
186 Feng Z, Zhang J. A dual role of BRCA1 in two distinct homologous recombination mediated repair in response to replication arrest. Nucleic Acids Res 2012;40:726-38. [PMID: 21954437 DOI: 10.1093/nar/gkr748] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 3.3] [Reference Citation Analysis]
187 Muñoz MC, Laulier C, Gunn A, Cheng A, Robbiani DF, Nussenzweig A, Stark JM. RING finger nuclear factor RNF168 is important for defects in homologous recombination caused by loss of the breast cancer susceptibility factor BRCA1. J Biol Chem 2012;287:40618-28. [PMID: 23055523 DOI: 10.1074/jbc.M112.410951] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29] [Article Influence: 4.1] [Reference Citation Analysis]
188 Telli ML, Jensen KC, Vinayak S, Kurian AW, Lipson JA, Flaherty PJ, Timms K, Abkevich V, Schackmann EA, Wapnir IL, Carlson RW, Chang PJ, Sparano JA, Head B, Goldstein LJ, Haley B, Dakhil SR, Reid JE, Hartman AR, Manola J, Ford JM. Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105. J Clin Oncol 2015;33:1895-901. [PMID: 25847929 DOI: 10.1200/JCO.2014.57.0085] [Cited by in Crossref: 145] [Cited by in F6Publishing: 78] [Article Influence: 24.2] [Reference Citation Analysis]
189 Mancini P, Angeloni A, Risi E, Orsi E, Mezi S. Standard of care and promising new agents for triple negative metastatic breast cancer. Cancers (Basel) 2014;6:2187-223. [PMID: 25347122 DOI: 10.3390/cancers6042187] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 4.4] [Reference Citation Analysis]
190 Atipairin A, Ratanaphan A. In Vitro Enhanced Sensitivity to Cisplatin in D67Y BRCA1 RING Domain Protein. Breast Cancer (Auckl) 2011;5:201-8. [PMID: 22084573 DOI: 10.4137/BCBCR.S8184] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
191 Pfäffle HN, Wang M, Gheorghiu L, Ferraiolo N, Greninger P, Borgmann K, Settleman J, Benes CH, Sequist LV, Zou L, Willers H. EGFR-activating mutations correlate with a Fanconi anemia-like cellular phenotype that includes PARP inhibitor sensitivity. Cancer Res 2013;73:6254-63. [PMID: 23966292 DOI: 10.1158/0008-5472.CAN-13-0044] [Cited by in Crossref: 27] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
192 Lewis KA, Lilly KK, Reynolds EA, Sullivan WP, Kaufmann SH, Cliby WA. Ataxia telangiectasia and rad3-related kinase contributes to cell cycle arrest and survival after cisplatin but not oxaliplatin. Mol Cancer Ther 2009;8:855-63. [PMID: 19372558 DOI: 10.1158/1535-7163.MCT-08-1135] [Cited by in Crossref: 19] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
193 Huber LJ, Yang TW, Sarkisian CJ, Master SR, Deng CX, Chodosh LA. Impaired DNA damage response in cells expressing an exon 11-deleted murine Brca1 variant that localizes to nuclear foci. Mol Cell Biol 2001;21:4005-15. [PMID: 11359908 DOI: 10.1128/MCB.21.12.4005-4015.2001] [Cited by in Crossref: 73] [Cited by in F6Publishing: 39] [Article Influence: 3.7] [Reference Citation Analysis]
194 Jin Z, Wang W, Jiang N, Zhang L, Li Y, Xu X, Cai S, Wei L, Liu X, Chen G, Zhou Y, Liu C, Li Z, Jin F, Chen B. Clinical Implications of iNOS Levels in Triple-Negative Breast Cancer Responding to Neoadjuvant Chemotherapy. PLoS One 2015;10:e0130286. [PMID: 26196284 DOI: 10.1371/journal.pone.0130286] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
195 Bunting SF, Callén E, Kozak ML, Kim JM, Wong N, López-Contreras AJ, Ludwig T, Baer R, Faryabi RB, Malhowski A, Chen HT, Fernandez-Capetillo O, D'Andrea A, Nussenzweig A. BRCA1 functions independently of homologous recombination in DNA interstrand crosslink repair. Mol Cell 2012;46:125-35. [PMID: 22445484 DOI: 10.1016/j.molcel.2012.02.015] [Cited by in Crossref: 196] [Cited by in F6Publishing: 175] [Article Influence: 21.8] [Reference Citation Analysis]
196 Castro E, Eeles R. The role of BRCA1 and BRCA2 in prostate cancer. Asian J Androl. 2012;14:409-414. [PMID: 22522501 DOI: 10.1038/aja.2011.150] [Cited by in Crossref: 63] [Cited by in F6Publishing: 53] [Article Influence: 7.0] [Reference Citation Analysis]